1. Home
  2. CINGW vs TREX Comparison

CINGW vs TREX Comparison

Compare CINGW & TREX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • TREX
  • Stock Information
  • Founded
  • CINGW N/A
  • TREX 1996
  • Country
  • CINGW United States
  • TREX United States
  • Employees
  • CINGW 13
  • TREX N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • TREX
  • Sector
  • CINGW Health Care
  • TREX
  • Exchange
  • CINGW Nasdaq
  • TREX Nasdaq
  • Market Cap
  • CINGW N/A
  • TREX N/A
  • IPO Year
  • CINGW 2021
  • TREX 1999
  • Fundamental
  • Price
  • CINGW $0.07
  • TREX $66.24
  • Analyst Decision
  • CINGW
  • TREX Buy
  • Analyst Count
  • CINGW 0
  • TREX 16
  • Target Price
  • CINGW N/A
  • TREX $81.87
  • AVG Volume (30 Days)
  • CINGW N/A
  • TREX 1.1M
  • Earning Date
  • CINGW N/A
  • TREX 10-28-2024
  • Dividend Yield
  • CINGW N/A
  • TREX N/A
  • EPS Growth
  • CINGW N/A
  • TREX 85.18
  • EPS
  • CINGW N/A
  • TREX 2.42
  • Revenue
  • CINGW N/A
  • TREX $1,249,686,000.00
  • Revenue This Year
  • CINGW N/A
  • TREX $6.41
  • Revenue Next Year
  • CINGW N/A
  • TREX $6.52
  • P/E Ratio
  • CINGW N/A
  • TREX $27.37
  • Revenue Growth
  • CINGW N/A
  • TREX 28.06
  • 52 Week Low
  • CINGW N/A
  • TREX $53.59
  • 52 Week High
  • CINGW N/A
  • TREX $101.91
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • TREX 47.42
  • Support Level
  • CINGW N/A
  • TREX $65.90
  • Resistance Level
  • CINGW N/A
  • TREX $68.45
  • Average True Range (ATR)
  • CINGW 0.00
  • TREX 2.00
  • MACD
  • CINGW 0.00
  • TREX 0.05
  • Stochastic Oscillator
  • CINGW 0.00
  • TREX 16.20

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: